Prevalence of High-Risk Human Papillomavirus Infections before and after Cervical Lesion Treatment, among Women Living with HIV

Timothée Dub, Sophie Le Cœur, Nicole Ngo-Giang-Huong, Wanmanee Matanasarawut, Pornnapa Suriyachai, Kannikar Saisawat, Chaiwat Putiyanun, Sudanee Buranabanjasatean, Prattana Leenasirimakul, Samreung Randaeng, Tristan Delory, Timothée Dub, Sophie Le Cœur, Nicole Ngo-Giang-Huong, Wanmanee Matanasarawut, Pornnapa Suriyachai, Kannikar Saisawat, Chaiwat Putiyanun, Sudanee Buranabanjasatean, Prattana Leenasirimakul, Samreung Randaeng, Tristan Delory

Abstract

Even when receiving combination antiretroviral therapy, women living with HIV are at high risk of human papillomavirus (HPV) infection and/or cervical lesions, including cancer. Using data from the PapilloV prospective cohort, we evaluated the prevalence of high-risk HPV (HR-HPV) infections after cervical lesion treatment and investigated factors associated with their carriage. Women were followed up for three years with annual Pap smear and HPV genotyping. We offered treatment to women presenting either a Pap smear with high-grade squamous intraepithelial lesion or higher, and/or a biopsy showing cervical intraepithelial neoplasia II or III. We compared the prevalence of HR-HPV infection at the time of first treatment indication and at the end of follow-up among women who received treatment and those who did not. Overall, 46 women had treatment indication. HR-HPV prevalence significantly decreased from 67% to 27% (p value = 0.001) in the 30 women who received treatment, while it did not significantly decrease (from 56% to 38%) in the 16 women who did not (p value = 0.257). Due to lack of statistical power, the 40% relative difference in HR-HPV carriage between treated and untreated women was not significant. In women living with HIV, the treatment of a cervical lesion may be beneficial for clearing HR-HPV infections.

Keywords: cervical lesion; human papillomavirus; women living with HIV.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of patient selection.

References

    1. Kantathavorn N., Mahidol C., Sritana N., Sricharunrat T., Phoolcharoen N., Auewarakul C., Teerayathanakul N., Taepisitpong C., Saeloo S., Sornsamdang G., et al. Genotypic distribution of human papillomavirus (HPV) and cervical cytology findings in 5906 Thai women undergoing cervical cancer screening programs. Infect. Agents Cancer. 2015;10:7. doi: 10.1186/s13027-015-0001-5.
    1. Marks M.A., Gupta S., Liaw K.-L., Tadesse A., Kim E., Phongnarisorn C., Wootipoom V., Yuenyao P., Vipupinyo C., Rugpao S., et al. Prevalence and correlates of HPV among women attending family-planning clinics in Thailand. BMC Infect. Dis. 2015;15:159. doi: 10.1186/s12879-015-0886-z.
    1. Phoolcharoen N., Kantathavorn N., Sricharunrat T., Saeloo S., Krongthong W. A population-based study of cervical cytology findings and human papillomavirus infection in a suburban area of Thailand. Gynecol. Oncol. Rep. 2017;21:73–77. doi: 10.1016/j.gore.2017.06.003.
    1. Delory T., Ngo-Giang-Huong N., Rangdaeng S., Chotivanich N., Limtrakul A., Putiyanun C., Suriyachai P., Matanasarawut W., Jarupanich T., Liampongsabuddhi P., et al. Human Papillomavirus infection and cervical lesions in HIV infected women on antiretroviral treatment in Thailand. J. Infect. 2017;74:501–511. doi: 10.1016/j.jinf.2017.02.007.
    1. Bollen L.J.M., Chuachoowong R., Kilmarx P., Mock P.A., Culnane M., Skunodom N., Chaowanachan T., Jetswang B., Neeyapun K., Asavapiriyanont S., et al. Human Papillomavirus (HPV) Detection among Human Immunodeficiency Virus–Infected Pregnant Thai Women: Implications for Future HPV Immunization. Sex. Transm. Dis. 2006;33:259–264. doi: 10.1097/01.olq.0000187208.94655.34.
    1. Ramautarsing R.A., Phanuphak N., Chaithongwongwatthana S., Wit F.W., Teeratakulpisarn N., Pankam T., Wijgert J.H. Cervical and anal HPV infection: Cytological and histological abnormalities in HIV-infected women in Thailand. J. Virus Erad. 2015;1:96–102. doi: 10.1016/S2055-6640(20)30485-4.
    1. Sohn A.H., Kerr S., Hansudewechakul R., Gatechompol S., Chokephaibulkit K., Dang H.L.D., Tran D.N.H., Achalapong J., Teeratakulpisarn N., Chalermchockcharoenkit A., et al. Risk Factors for Human Papillomavirus Infection and Abnormal Cervical Cytology Among Perinatally Human Immunodeficiency Virus-Infected and Uninfected Asian Youth. Clin. Infect. Dis. 2018;67:606–613. doi: 10.1093/cid/ciy144.
    1. Verrier F., Le Coeur S., Delory T. Cervical Human Papillomavirus Infection (HPV) and High Oncogenic Risk Genotypes among Women Living with HIV in Asia: A Meta-Analysis. J. Clin. Med. 2021;10:1911. doi: 10.3390/jcm10091911.
    1. Petry K.U., Horn J., Luyten A., Mikolajczyk R.T. Punch biopsies shorten time to clearance of high-risk human papillomavirus infections of the uterine cervix. BMC Cancer. 2018;18:318. doi: 10.1186/s12885-018-4225-9.
    1. Bollen L.J.M., Tjong-A-Hung S.P., Van Der Velden J., Mol B.W., Boer K., Kate F.J.W.T., Bleker O.P., Ter Schegget J. Clearance of Cervical Human Papillomavirus Infection by Treatment for Cervical Dysplasia. Sex. Transm. Dis. 1997;24:456–460. doi: 10.1097/00007435-199709000-00003.
    1. Adebamowo S.N., Famooto A., Dareng E., Olawande O., Olaniyan O., Offiong R., Adebamowo C., ACCME Research Group as part of the H3Africa Consortium Clearance of Type-Specific, Low-Risk, and High-Risk Cervical Human Papillomavirus Infections in HIV-Negative and HIV-Positive Women. J. Glob. Oncol. 2018;4:1–12. doi: 10.1200/JGO.17.00129.
    1. Aerssens A., Claeys P., Garcia A., Sturtewagen Y., Velasquez R., Broeck D.V., Vansteelandt S., Temmerman M., Cuvelier C.A. Natural history and clearance of HPV after treatment of precancerous cervical lesions. Histopathology. 2008;52:381–386. doi: 10.1111/j.1365-2559.2007.02956.x.
    1. Guo Y.-L., You K., Qiao J., Zhao Y.-M., Liu C.-R., Geng L. Natural history of infections with high-risk HPV in Chinese women with abnormal cervical cytology findings at baseline. Int. J. Gynecol. Obstet. 2010;110:137–140. doi: 10.1016/j.ijgo.2010.03.021.
    1. Fregonese F., Collins I.J., Jourdain G., LeCoeur S., Cressey T.R., Ngo-Giang-Houng N., Banchongkit S., Chutanunta A., Techapornroong M., Lallemant M. Predictors of 5-Year Mortality in HIV-Infected Adults Starting Highly Active Antiretroviral Therapy in Thailand. JAIDS J. Acquir. Immune Defic. Syndr. 2012;60:91–98. doi: 10.1097/QAI.0b013e31824bd33f.
    1. Costa S., De Simone P., Venturoli S., Cricca M., Zerbini M.L., Musiani M., Terzano P., Santini D., Cristiani P., Syrjänen S., et al. Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization. Gynecol. Oncol. 2003;90:358–365. doi: 10.1016/S0090-8258(03)00268-3.
    1. Travassos A.G., Netto E., Xavier-Souza E., Nóbrega I., Adami K., Timbó M., Abbehusen K., Fernandes S., Duran C., Haguihara T., et al. Predictors of HPV incidence and clearance in a cohort of Brazilian HIV-infected women. PLoS ONE. 2017;12:e0185423. doi: 10.1371/journal.pone.0185423.
    1. Huber B., Wang J., Roden R., Kirnbauer R. RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates. J. Clin. Med. 2021;10:1044. doi: 10.3390/jcm10051044.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅